Perioperative QST and incision pain mapping assessment
Perioperative QST and incision pain mapping assessment: Participants will undergo non-invasive perioperative quantitative sensory testing and incision-centered mechanical pain mapping at prespecified time points. These assessments are observational and will not determine or modify clinical anesthesia, analgesia, or surgical management.
Study summary
Postoperative pain remains a common and clinically important burden after thoracic surgery and may progress to chronic postsurgical pain. Conventional pain assessment mainly relies on patient-reported pain intensity and analgesic consumption, which may not fully capture peri-incisional sensory abnormalities, mechanical hyperalgesia, or central sensitization.
This prospective observational pilot cohort study aims to evaluate the feasibility and acceptability of perioperative quantitative sensory testing (QST) and incision pain mapping in adult patients undergoing elective thoracoscopic or robotic-assisted lung resection. Participants will undergo baseline assessment before surgery, serial postoperative pain assessments during the first 72 hours, QST and mechanical hyperalgesia pain mapping at 48-72 hours after surgery, and follow-up assessments at discharge, 1 month, and 3 months after surgery.
The primary feasibility outcomes include recruitment rate, QST completion rates, follow-up completion rates, QST-related discontinuation rate, study-related adverse events, and data completeness. The main clinical mechanistic outcome is the area of peri-incisional mechanical hyperalgesia at 48-72 hours after surgery. Secondary outcomes include acute postoperative pain intensity, pain burden over 72 hours, opioid consumption, quality of recovery, QST changes, pain-map characteristics, and chronic postsurgical pain at 3 months.
This study will not assign or modify therapeutic interventions. All anesthetic, surgical, and analgesic management will be determined by the routine clinical care team. The study is expected to provide feasibility data, preliminary effect estimates, and mechanistic information for future larger perioperative pain studies.
Eligibility
Sex
MALE
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
1. Male
2. Scheduled to undergo elective thoracoscopic or robotic-assisted lung resection.
3. American Society of Anesthesiologists physical status I to III.
4. Able to understand and communicate adequately and to complete study questionnaires independently or with assistance from study staff.
5. Willing to undergo QST assessment, perioperative venous blood sampling, and postoperative follow-up.
6. Able and willing to provide written informed consent.
Exclusion Criteria:
1. Definite chronic chest wall, shoulder, back, or upper limb pain with an average 2. Numeric Rating Scale score of 3 or higher during the preceding week.
3\. Definite painful neuropathic disease or long-term use of opioids or other analgesics for more than 2 weeks.
4\. Peripheral neuropathy, spinal cord disease, or other neurological disease that may substantially interfere with interpretation of QST results.
5\. Severe cognitive impairment, psychiatric disorder, communication disorder, or inability to complete questionnaires and QST assessments.
6\. Active infection, active autoimmune disease, or other disease condition that may substantially affect inflammatory protein measurements.
7\. Emergency surgery, conversion to open thoracotomy, extensive chest wall resection, or severe intraoperative complications.
8\. Any condition that, in the opinion of the investigator, makes the participant unsuitable for continued participation in the study.
Primary outcome measure(s)
Recruitment Rate — Baseline Proportion of eligible patients who provide written informed consent and are enrolled in the study.
Completion Rate of Baseline Quantitative Sensory Testing — Preoperative period, 1 to 3 days before surgery Proportion of enrolled participants who complete the planned baseline QST assessment before surgery.
Completion Rate of Postoperative QST and Incision Pain Mapping — 48 to 72 hours after surgery Proportion of enrolled participants who complete the core postoperative QST assessment and incision-centered mechanical hyperalgesia pain mapping.
Completion Rate of 1-month Follow-up — 1 month after surgery Proportion of enrolled participants who complete the planned 1-month postoperative follow-up assessment.
Completion Rate of 3-month Pain Outcome Follow-up — 90 ± 14 days after surgery Proportion of enrolled participants who complete the primary 3-month postoperative pain outcome assessment.
QST-related Discontinuation Rate — From baseline assessment to 3 months after surgery Proportion of participants who discontinue QST or pain mapping prematurely because of pain intolerance, fatigue, anxiety, or other participant-related reasons.
Study-related Adverse Event Rate — From baseline assessment to 3 months after surgery Proportion of participants with study-related adverse events, including marked discomfort, transient pain exacerbation, local discomfort related to QST or pain mapping, or adverse events related to blood sampling.
Data Completeness of Key Study Variables — From baseline assessment to 3 months after surgery Proportion of missing data for key variables
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.